Figure 2.

Thrombin generation in FVIII-deficient plasma. Thrombin generation in FVIII-deficient plasma in the presence of emicizumab (A), anti-antithrombin nanobodies (B), or anti-TFPI antibodies (C). In all cases, the addition of the antibodies increases thrombin generation compared with FVIII-deficient plasma alone. (A) Factor XIa-induced thrombin generation in the absence or presence of emicizumab (0-50 μg/mL; P.J.L., unpublished data). (B) Tissue factor-induced thrombin generation in the absence or presence of anti-antithrombin nanobodies.⁵² (C) Tissue factor-induced thrombin generation in the absence or presence of polyclonal anti-TFPI antibodies.⁵³